相似文献/References:
[1]王 鑫,王艳翚.基本药物制度与基本医疗保险制度的衔接研究[J].卫生经济研究,2017,(10):7.
[2]刘 昉,李翠翠,马 健,等.基层用药公平可及性评价研究[J].卫生经济研究,2018,(04):46.
[3]李晓春,侯艳红.国家基本药物制度的完善及走向[J].卫生经济研究,2018,(12):34.
LI Xiao-chun,HOU Yan-hong.The Improvement and Trend of the National Basic Drug System[J].Journal Press of Health Economics Research,2018,(10):34.
[4]吴玉霞,徐 伟,蔡功杰,等.基本药物可获得性影响因素研究——基于25省监测点数据的实证分析[J].卫生经济研究,2018,(12):37.
WU Yu-xia,XU Wei,CAI Gong-jie,et al.Study on the Factors Affecting the Availability of Essential Drugs——An Empirical Analysis Based on Data from 25 Provinces[J].Journal Press of Health Economics Research,2018,(10):37.
[5]李孟林,徐 伟,杜雯雯,等.我国上市专利药品可获得性实证研究[J].卫生经济研究,2019,(12):59.
LI Meng-lin,XU Wei,DU Wen-wen,et al.Empirical Study on the Availability of Patented Drugs in China[J].Journal Press of Health Economics Research,2019,(10):59.
[6]陈玲玲,徐 伟,尚波波,等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究,2020,(12):17.
CHEN Ling-ling,XU Wei,SHANG Bo-bo,et al.Research on the Availability of National Negotiated Drugs——An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou[J].Journal Press of Health Economics Research,2020,(10):17.
[7]曹 庄,李赛赛,曹人元,等.国家医保谈判药品落地情况研究——基于5市17种国谈抗癌药使用及报销数据的分析[J].卫生经济研究,2022,39(7):53.
CAO Zhuang,LI Saisai,CAO Renyuan,et al.Research on the Accessibility of National Medical Insurance Negotiation Drugs ——An Analysis Based on the Usage and Reimbursement Data of 17 National Negotiated Anticancer Drugs in Five Cities[J].Journal Press of Health Economics Research,2022,39(10):53.
[8]罗 银,吴雨欣,杨赐然,等.湖北省国谈药可获得性研究
——基于公立医院和零售药店的数据分析[J].卫生经济研究,2024,41(08):8.
LUO Yin,WU Yuxin,YANG Ciran,et al.Study on the Availability of National Negotiated Drugs in Hubei Province
——Based on the Data Analysis of Public Hospitals and Retail Pharmacies[J].Journal Press of Health Economics Research,2024,41(10):8.